Deniz Kural ^UDM

Deniz Kural, Co-Founder of Totient, leads an AI-driven biotechnology company that harnesses tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient's innovative approach involves reconstructing antibodies from tissues affected by autoimmunity, infections, and cancer, collected from patients with exceptional immune responses. With a starting population of over 50,000 samples, Totient has successfully reconstructed antibodies against known and novel extracellular oncology targets, including GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, GPR83, and others undisclosed. Deniz Kural's leadership drives Totient's mission to revolutionize biotechnology by leveraging AI to discover and develop antibodies tailored to specific tissues, opening new possibilities in the treatment of various diseases.